Examining adjuvant radiation dose in head and neck squamous cell carcinoma
Head & Neck2019Vol. 41(7), pp. 2133–2142
Citations Over Time
Vladimir Avkshtol, Elizabeth A. Handorf, John A. Ridge, Brooke K. Leachman, Jeffrey Liu, Jessica R. Bauman, Thomas J. Galloway
Abstract
There was no survival benefit from postoperative dose escalation above EQD2 60 Gy even in a high-risk cohort.
Related Papers
- → Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine(2019)8 cited
- → Adjuvant Formulations for Experimental Vaccines(2003)13 cited
- Immune Adjuvant Effect of CFNCpG Motif on Antigen of Inactivated BVDV1(2008)
- Research progress of aluminum adjuvant(2015)
- → ADJUVANTS(1994)